The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia.

Clin Cancer Res

Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA.

Published: November 2011

Purpose: To further our understanding of the biology and prognostic significance of various chromosomal 13q14 deletions in chronic lymphocytic leukemia (CLL).

Experimental Design: We analyzed data from SNP 6.0 arrays to define the anatomy of various 13q14 deletions in a cohort of 255 CLL patients and have correlated two subsets of 13q14 deletions (type I exclusive of RB1 and type II inclusive of RB1) with patient survival. Furthermore, we measured the expression of the 13q14-resident microRNAs by quantitative PCR (Q-PCR) in 242 CLL patients and subsequently assessed their prognostic significance. We sequenced all coding exons of RB1 in patients with monoallelic RB1 deletion and have sequenced the 13q14-resident miR locus in all patients.

Results: Large 13q14 (type II) deletions were detected in approximately 20% of all CLL patients and were associated with shortened survival. A strong association between 13q14 type II deletions and elevated genomic complexity, as measured through CLL-FISH or SNP 6.0 array profiling, was identified, suggesting that these lesions may contribute to CLL disease evolution through genomic destabilization. Sequence and copy number analysis of the RB1 gene identified a small CLL subset that is RB1 null. Finally, neither the expression levels of the 13q14-resident microRNAs nor the degree of 13q14 deletion, as measured through SNP 6.0 array-based copy number analysis, had significant prognostic importance.

Conclusions: Our data suggest that the clinical course of CLL is accelerated in patients with large (type II) 13q14 deletions that span the RB1 gene, therefore justifying routine identification of 13q14 subtypes in CLL management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207001PMC
http://dx.doi.org/10.1158/1078-0432.CCR-11-0785DOI Listing

Publication Analysis

Top Keywords

13q14 deletions
20
prognostic significance
12
cll patients
12
13q14
9
deletions chronic
8
chronic lymphocytic
8
lymphocytic leukemia
8
13q14-resident micrornas
8
13q14 type
8
type deletions
8

Similar Publications

The treatment of multiple myeloma (MM) has significantly advanced; however, the underlying genetic mechanisms remain elusive. Clonal events and genetic alterations are recognized as pivotal in the pathogenesis of MM. It is now understood that a multitude of gene mutations, including those affecting RAS, , , and 1q21 amplification, are prevalent in this disease.

View Article and Find Full Text PDF
Article Synopsis
  • - Breast cancer (BCa) presents a significant health challenge worldwide, with many tumors showing extensive genetic alterations known as somatic copy number alterations (CNAs) that influence tumor behavior and patient outcomes.
  • - Loss of the chromosome segment 13q14.2 is a common and important CNA found in up to 63% of BCa patients, associated with poorer survival rates, and its impact is complex, enhancing both cancer cell growth and immune responses in the tumor environment.
  • - This loss of 13q14.2 also increases the effectiveness of BCL2 inhibitors in treating BCa, suggesting it could be used as a biomarker to help predict patient prognosis and guide treatment options.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on early preterm infants who are small for gestational age (SGA) and examines the role of genetic disorders in their high rates of morbidity and mortality.
  • Researchers conducted a retrospective analysis of infants born between 2000-2020, comparing the prevalence of genetic disorders in SGA infants (with and without congenital anomalies) to those who were appropriate for gestational age (AGA).
  • Findings revealed that genetic disorders were identified in a small percentage of SGA infants, with trisomies 13, 18, and 21 being the most common, highlighting the need for further research on genetic factors contributing to their health outcomes.
View Article and Find Full Text PDF

Fluorescence in situ hybridization (FISH) is a reliable method to detect a deletion on chromosome 13q14. Currently, three commercial probes are available for FISH testing in clinical cytogenetics laboratories, RB1, D13S319, and D13S25, with the D13S319 probe most commonly used for 13q deletion. In this study, we compared FISH test results among these three probes in CLL cases with positive 13q deletion.

View Article and Find Full Text PDF

Background Chronic lymphocytic leukemia (CLL) starts in white blood cells in the peripheral blood (stages 0 and 1). In CLL, leukemia cells often build up slowly. Many gene mutations are associated with CLL, such as trisomy 12, 13q14 deletion, and 17q deletion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!